Among the 27 tested cytokines, IL-1Ra, IL-4, IL-7, IL-13, and PDGF-BB were found to be predictors of OS in MM patients treated with bortezomib-based regimens in univariate models, and IL-1Ra and IL-4 maintained this significance in the multivariate model. This evidence concerns the gene IL4 and Miyoshi myopathy.